Page 104 - 51 the significance--29.2_opt

23. Reasner CA, Goke B. Overcoming the barriers to effective glycaemic control for
type 2 diabetes. The British Journal of Diabetes & Vascular Disease 2002;2(290-295).
24. AACE/ACE. Statement by an AACE/ACE Consensus Panel on Type 2 Diabetes Mellitus:
An Algorithm for Glycemic Control. Endocr Pract 2009;15:540-559.
25. ADA. Standards of medical care in diabetes--2008. Diabetes Care 2008;31 Suppl 1:
S12-54.
26. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular
events. Diabetes Care;33(6):1389-94.
27. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Jr., Selby JV. Hypoglycemic
episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA
2009;301(15):1565-72.
28. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary.
The Task Force on Diabetes and Cardiovascular Diseases of the European Society
of Cardiology (ESC) and of the European Association for the Study of Diabetes
(EASD). Eur Heart J 2007;28(1):88-136.
29. UKPDS. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
N Engl J Med 2008;359(15):1565-76.
30. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008;359(15):
1618-20.
31. Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes.
Diabetes Res Clin Pract 2009;86 Suppl 1:S2-6.
32. Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more
than just tight glucose control necessary to prevent diabetic complications? J Clin
Endocrinol Metab 2009;94(2):410-5.
33. UKPDS. Association of glycaemia with macrovascular and microvascular compli-
cations of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;
321(7258):405-12.
34. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing
therapies in type 2 diabetes mellitus based on patient characteristics: what we
know and what we need to know. J Clin Endocrinol Metab 2010;95(4):1566-74.
35. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S.
adults? Diabetes Care 2008;31(1):81-86.
36. Yurgin N, Secnik K, Lage MJ. Antidiabetic prescriptions and glycemic control in
German patients with type 2 diabetes mellitus: a retrospective database study.
Clin Ther 2007;29(2):316-25.
37. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med
2008;359(11):1092-5.
38. ACCORD, Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, et al. Effects
of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358(24):2545-59.
39. ADVANCE. Intensive blood glucose control and vascular outcomes in patients with
type 2 diabetes. N Engl J Med 2008;358(24):2560-72.
40. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose
control and vascular complications in veterans with type 2 diabetes. N Engl J Med
2009;360(2):129-39.
41. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive
glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89.
42. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK,
et al. Secondary prevention of macrovascular events in patients with type 2 diabetes
in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular
Events): a randomised controlled trial. Lancet 2005;366(9493):1279-89.
43. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al.
Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting
cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes
Care 2007;30(11):2773-8.
44. Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07:
pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Vasc Health Risk Manag 2007;3(4):355-70.
45. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM.
The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with
type 2 diabetes and previous myocardial infarction: results from the PROactive
(PROactive 05) Study. J Am Coll Cardiol 2007;49(17):1772-80.

104